Study guide
8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions
Key Takeaways Explain This Topic AI
Bipolar disorder exhibits the highest lifetime co-occurring substance use rate (>60%) of all psychiatric conditions; definitive mood stabilization is an absolute clinical prerequisite for achieving substance use remission.
Antidepressant monotherapy is strictly contraindicated in bipolar disorder with co-occurring SUD due to the substantial risk of inducing manic switches, mixed episodes, and rapid cycling.
Second-generation long-acting injectable (LAI) antipsychotics (e.g., paliperidone palmitate, aripiprazole lauroxil) decouple medication adherence from active substance use cravings, significantly reducing psychotic relapses and hospitalizations.
Clozapine uniquely demonstrates direct reductions in substance cravings and consumption in refractory schizophrenia, but requires strict ANC monitoring and proactive dose reduction upon tobacco cessation due to CYP1A2 de-induction.
Borderline Personality Disorder (BPD) with severe polysubstance use mandates Dialectical Behavior Therapy (DBT) with Linehan's SUD adaptations (dialectical abstinence, behavioral chain analysis) and strict avoidance of PRN benzodiazepines.
Last updated: September 2026
8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions
Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) specializing in addictions must master the complex psychopharmacology, pharmacokinetic interactions, and evidence-based behavioral therapies required to stabilize patients presenting with co-occurring severe mental illness (SMI)—including Bipolar I/II Disorder, Schizophrenia spectrum disorders, and Borderline Personality Disorder—co-occurring with severe polysubstance use.
- 1. Bipolar I & II Disorder with Co-Occurring Substance Use Disorders
- Epidemiology & Clinical Interdependence
Among all major psychiatric conditions, Bipolar I and Bipolar II Disorders exhibit the highest comorbidity with substance use disorders, with lifetime prevalence estimates exceeding 60% to 65% . The relationship is bidirectional, pernicious, and mutually destabilizing:
Manic Disinhibition: Hypomanic and manic episodes produce grandiosity, hypersexuality, impulsivity, and impaired risk appraisal, driving patients directly into binge substance use—predominantly stimulants (cocaine, methamphetamine) and alcohol.
Dysphoric Self-Medication: Depressive and mixed episodes characterized by intense psychic pain, irritability, and insomnia frequently prompt heavy alcohol or sedative consumption in a desperate attempt to induce sleep or blunt emotional agony.
Substance-Induced Destabilization: Stimulant and alcohol use accelerates episode frequency, triggers rapid cycling (≥4 mood episodes per year), precipitates treatment-refractory mixed states, and drastically elevates suicide completion rates.
The Clinical Axiom: Mood stabilization is the absolute prerequisite for achieving durable substance use remission. Attempting to achieve sustained abstinence while mania or hypomania remains unmedicated is clinically futile. The Manic-Substance Destabilization Cascade:
- [Bipolar Diathesis: Unstable Cortico-Limbic Mood Regulation]
- │
- ▼
- [Acute Manic / Mixed Mood Onset]
- (Grandiosity, Decreased Sleep Need, Impulsivity)
- │
- ▼
- [Severe Substance Binge Episode]
- (Cocaine, Methamphetamine, Binge Alcohol)
- │
- ▼
- [Profound Dopaminergic / Serotonergic Neurotransmitter Depletion]
- │
- ▼
- [Post-Binge Catastrophic Crash into MDD]
- (Intense Hopelessness, Severe Suicidality, Exhaustion)
- │
- ▼
- [Urgent Chemical Re-Dosing: Rapid Cycling & Treatment Resistance]
- Evidence-Based Pharmacotherapy for Bipolar-SUD Comorbidity
- Mood Stabilizers
Lithium Carbonate: The gold standard mood stabilizer with unique, independently verified antisuicidal properties . It effectively treats acute mania and provides maintenance against depressive and manic recurrences.
Therapeutic Serum Trough Levels: 0.8 to 1.2 mEq/L for acute mania; 0.6 to 1.0 mEq/L for maintenance.
Essential Safety Monitoring: Baseline and periodic serum creatinine, Blood Urea Nitrogen (BUN), estimated GFR, Thyroid Stimulating Hormone (TSH), calcium, and baseline ECG.
Critical SUD Safety Warning: Lithium has a very narrow therapeutic index. In patients with active Alcohol Use Disorder or stimulant dependence, episodes of dehydration, excessive diaphoresis, vomiting, diarrhea, or NSAID use dramatically decrease renal lithium clearance, precipitating severe lithium toxicity (coarse tremors, hyperreflexia, ataxia, confusion, seizures, acute tubular necrosis, and coma).
Divalproex Sodium / Valproate: Particularly efficacious in patients with mixed manic states, rapid cycling, and co-occurring substance use , often demonstrating superior clinical retention compared to lithium in polysubstance cohorts.
Therapeutic Serum Trough Levels: 50 to 125 mcg/mL.
Essential Safety Monitoring: Baseline and periodic Liver Function Tests (LFTs: AST, ALT, Total Bilirubin), Complete Blood Count with differential (platelet counts), and serum ammonia if the patient develops unexplained lethargy or cognitive slowing (valproate-induced hyperammonemic encephalopathy).
Black Box Warnings & Cautions: Hepatotoxicity, pancreatitis, dose-dependent thrombocytopenia, and severe teratogenicity (major congenital malformations including neural tube defects / spina bifida and neurodevelopmental deficits). Strictly contraindicated in women of childbearing potential unless effective, reliable contraception is documented and alternative agents have failed.
Second-Generation Antipsychotics (SGAs)
Quetiapine (XR/IR): FDA-approved for bipolar mania, bipolar maintenance, and bipolar depression. Demonstrates efficacy in reducing anxiety, treating insomnia, and stabilizing mood in patients with co-occurring AUD. Clinical Cautions: Sedation, significant weight gain, hypertriglyceridemia, insulin resistance, and potential for diversion/misuse in closed institutional or correctional settings ("quell", "baby heroin").
Aripiprazole: A partial dopamine D2/D3 agonist and 5-HT1A partial agonist with 5-HT2A antagonism. Favorable metabolic profile, non-sedating, excellent for acute mania and maintenance. Caution for akathisia and impulse-control disorders (gambling, compulsive spending).
Lurasidone: FDA-approved for bipolar depression (monotherapy or adjunctive with lithium/valproate). Favorable weight and lipid profile. Administration Requirement: Must be administered with food containing at least 350 calories to achieve adequate bioavailability.
Strict Avoidance of Antidepressant Monotherapy
Prescribing antidepressant monotherapy (SSRIs, SNRIs, TCAs, or MAOIs) without an effective therapeutic mood stabilizer in patients with Bipolar I or Bipolar II disorder is strictly contraindicated . Antidepressants trigger manic switches , precipitate severe irritable mixed states, accelerate cycle frequency, and induce rapid cycling—substantially worsening substance use and suicide risk.
- 2. Schizophrenia Spectrum Disorders with Co-Occurring SUD
- The Tobacco Use Disorder Epidemic in Schizophrenia
Tobacco smoking prevalence among individuals diagnosed with schizophrenia ranges from 70% to greater than 80% , representing a rate three- to fourfold higher than the general population. This disproportionate smoking rate is driven by profound neurobiological factors:
Alpha-7 Nicotinic Acetylcholine Receptor (α7-nAChR) Pathology: Post-mortem and genetic studies reveal severe deficits in low- and high-affinity nicotinic receptor expression in the hippocampus, thalamus, and prefrontal cortex of patients with schizophrenia.
Sensory Gating Deficits (P50 Auditory Gating): Normal brains filter out repetitive, irrelevant environmental auditory stimuli. Patients with schizophrenia exhibit impaired P50 gating, resulting in sensory overload and cognitive fragmentation. High-dose nicotine consumption transiently corrects this P50 deficit, providing temporary relief from cognitive disorganization.
Counteracting Antipsychotic Adverse Effects: Nicotine stimulates prefrontal dopamine release, mitigating antipsychotic-induced parkinsonism, cognitive slowing, and emotional blunting.
Critical Pharmacokinetic Interaction: Tobacco Smoke and CYP1A2 Induction
A vital advanced practice pharmacology pearl involves the metabolic interaction between tobacco smoke and psychotropics metabolized by Cytochrome P450 1A2 (CYP1A2) :
Mechanism: The polycyclic aromatic hydrocarbons (tar) in burned tobacco smoke— NOT nicotine itself —are potent, robust inducers of hepatic CYP1A2.
Clinical Consequence: Heavy smokers require significantly higher doses of CYP1A2 substrates, most notably Clozapine and Olanzapine .
The Smoking Cessation Toxicity Trap: When a patient stabilized on clozapine or olanzapine stops smoking (e.g., during hospital admission or starting a tobacco cessation program), the enzymatic induction ceases over 1 to 2 weeks . Consequently, CYP1A2 clearance plummets, and serum concentrations of clozapine can spike by 50% to 100% , precipitating severe, life-threatening toxicity (profound sedation, seizures, orthostatic hypotension, paralytic ileus, cardiac arrest).
APRN Action: When a patient on clozapine or olanzapine reduces or ceases tobacco use, the APRN must proactively reduce the dose by 30% to 50% , monitor serum drug concentrations, and follow clinical signs of toxicity closely. Tobacco Smoke - CYP1A2 Pharmacokinetic Interaction:
- [Active Heavy Smoking]
- (Polycyclic Aromatic Hydrocarbons)
- │
- ▼
- [Potent Induction of Hepatic CYP1A2]
- │
- ▼
- [Accelerated Clearance of Clozapine & Olanzapine]
- (High daily doses required to achieve therapeutic levels)
────────────────── Patient Stops Smoking ──────────────────
- [CYP1A2 Enzyme Induction Resolves over 1-2 Weeks]
- │
- ▼
- [Hepatic Clearance Drops by 50%]
- │
- ▼
- [Serum Clozapine Concentrations Spike Precipitously!]
- (Clinical Toxicity: Delirium, Grand Mal Seizures, Paralytic Ileus, Aspiration)
- │
- ▼
- [MANDATORY APRN ACTION: Proactively reduce dose by 30-50% & monitor levels]
- Tobacco Cessation Pharmacotherapy in Schizophrenia
Tobacco cessation must be prioritized without fear of psychiatric destabilization:
Dual Nicotine Replacement Therapy (NRT): Combining a high-dose long-acting transdermal nicotine patch (21 mg/day) with short-acting NRT (nicotine gum, lozenge, or nasal spray) provides basal coverage while quenching acute breakthrough cravings.
Varenicline: An α4β2 nicotinic acetylcholine receptor partial agonist. The landmark EAGLES trial established that varenicline is highly effective and does not increase neuropsychiatric adverse events, suicidal ideation, or psychotic exacerbations in stable psychiatric populations. It represents the most effective single oral agent for tobacco cessation in schizophrenia.
Cannabis, Stimulants & Second-Generation Long-Acting Injectables (LAIs)
Cannabis & Psychosis: High-potency cannabis (delta-9-THC) and synthetic cannabinoids (K2/Spice) are potent triggers of acute psychotic exacerbations, accelerate conversion from prodromal states to formal schizophrenia, and increase psychiatric rehospitalizations by twofold.
Second-Generation LAI Antipsychotics: The cornerstone of integrated management in co-occurring schizophrenia and SUD. Cognitive deficits, executive dysfunction, and episodic substance binges severely undermine oral pill adherence. LAIs decouple medication delivery from daily substance cravings:
Paliperidone Palmitate (Invega Sustenna / Trinza): Administered monthly or every 3 months. Maintains steady-state D2 receptor blockade without daily cognitive decision-making.
Aripiprazole Lauroxil (Aristada) / Aripiprazole Monohydrate (Abilify Maintena): Administered every 4 to 8 weeks. Low metabolic risk, partial agonist profile.
Clinical Impact: LAIs dramatically reduce psychotic relapses, decrease substance use frequency, prevent emergency department visits, and eliminate the risk of accidental overdose resulting from erratic oral dosing.
Clozapine's Unique Anti-Addiction Efficacy: Clozapine is the gold-standard atypical antipsychotic for treatment-resistant schizophrenia. Uniquely, numerous clinical trials demonstrate that clozapine produces substantial, direct reductions in alcohol, cannabis, and cocaine cravings and consumption. Clozapine requires strict monitoring of the Absolute Neutrophil Count (ANC) via the national Clozapine REMS system (discontinue if ANC falls <1000/mcL due to risk of fatal agranulocytosis).
- 3. Borderline Personality Disorder (BPD) & Severe Polysubstance Use
- The Clinical Challenge
Borderline Personality Disorder (BPD) co-occurs with substance use disorders in over 50% of clinical cases . BPD is characterized by pervasive patterns of affective dysregulation, intense fear of abandonment, chronic feelings of emptiness, extreme interpersonal reactivity, severe impulsivity, and recurrent non-suicidal self-injury (NSSI) or suicide gestures. Polysubstance misuse functions as an external chemical attempt to escape unbearable emotional agony and regulate overwhelming inner distress.
Dialectical Behavior Therapy (DBT) Adapted for SUD (DBT-SUD)
Developed by Marsha Linehan, DBT is the definitive evidence-based psychotherapeutic intervention for BPD. For co-occurring substance use, specific adaptations (DBT-SUD) are integrated into standard treatment: Core Components of Linehan's DBT-SUD Framework:
1. Dialectical Abstinence:
Synthesis of two polarized clinical stances:
- [Absolute Commitment to Abstinence] <── DIALECTICAL SYNTHESIS ──> [Radical Acceptance & Rapid Harm Reduction]
- Stance A: "Never using again is the only goal; 100% commitment right now."
- Stance B: "If a slip occurs, eliminate shame, analyze the lapse instantly, and resume recovery within hours."
2. Behavioral Chain Analysis (BCA):
Meticulous micro-analysis of every lapse:
[Vulnerability Factors] ──> [Prompting Event] ──> [Cognitive / Emotional Links] ──> [Substance Urge] ──> [Use Behavior] ──> [Consequences]
3. The Four Core Skill Modules:
• Mindfulness: Wise Mind; observing and describing emotions non-judgmentally.
• Distress Tolerance: TIPP skills (Temperature, Intense exercise, Paced breathing, Paired muscle relaxation); urge surfing.
• Emotion Regulation: Identifying emotions, opposite action to change unhelpful emotional states.
• Interpersonal Effectiveness: DEAR MAN; setting firm interpersonal boundaries, asserting needs without conflict.
Dialectical Abstinence: Traditional addiction treatment insists on absolute abstinence, which can induce the disastrous "abstinence violation effect" (a slip leads to total collapse, overwhelming shame, and catastrophic relapse). Conversely, pure harm reduction may unintentionally endorse complacency. Dialectical abstinence synthesizes these polarities: the patient makes a 100% commitment to total abstinence prior to any use, but if a slip occurs, the clinician immediately activates radical acceptance, eliminates moral judgment, conducts an immediate behavioral chain analysis, and restores safety within hours.
Attachment Strategies & Therapist Boundaries: Patients with BPD often alternate between idealization and devaluation ("splitting") of clinical staff. The APRN must establish rock-solid professional boundaries, maintain consistent treatment parameters, avoid rescue fantasies, and utilize interprofessional team consultation to prevent clinician burnout.
Pharmacotherapy Safeguards & Prescribing Precautions in BPD
Strict Avoidance of Habit-Forming Controlled Substances: The prescription of PRN benzodiazepines, barbiturates, carisoprodol, or sedative-hypnotics is strictly contraindicated . Patients with BPD exhibit high impulsivity during acute interpersonal crises; access to PRN sedatives leads to rapid dose escalation, severe behavioral disinhibition, accidental or deliberate overdose, and perpetuates reliance on chemical coping.
Targeted Symptom Pharmacotherapy: Psychopharmacology plays an adjunctive, secondary role to DBT in BPD. Medications are selected for specific symptom dimensions:
Affective Instability / Anger: Low-dose mood stabilizers (e.g., lamotrigine, topiramate) or second-generation antipsychotics (e.g., low-dose aripiprazole, quetiapine).
Impulsivity / Dysphoria: SSRIs may provide modest benefits for co-occurring depressive or anxiety symptoms, though evidence for core BPD traits is limited.
Structured Crisis Plans: Patients must have an explicit, written behavioral crisis plan that prioritizes non-pharmacological distress tolerance (e.g., ice-water facial immersion [mammalian dive reflex], intense physical exercise, reaching out to DBT phone coaching) rather than emergency room visits for sedative injections.
4. SMI, SUD Interactions, and Pharmacotherapy Safeguards
Severe Mental Illness Co-Occurring SUD Profile Preferred Pharmacotherapies Pharmacological Safeguards & Black Box Cautions
Bipolar I / II Disorder Stimulants (Cocaine/Meth), Alcohol, Cannabis Lithium , Divalproex , Quetiapine, Aripiprazole, Lurasidone Avoid antidepressant monotherapy (manic switch); monitor lithium levels/hydration; monitor valproate LFTs/platelets/ammonia
Schizophrenia / Schizoaffective Tobacco (>80%), Cannabis, Cocaine, Alcohol Second-Generation LAIs (Paliperidone, Aripiprazole), Clozapine , Varenicline, Dual NRT Tobacco smoke induces CYP1A2 ; reduce clozapine/olanzapine 30-50% on smoking cessation; Clozapine REMS (ANC monitoring)
Borderline Personality (BPD) Polysubstance (Sedatives, Opioids, Alcohol, Stimulants) Adjunctive low-dose SGAs / mood stabilizers paired with DBT-SUD Strictly avoid PRN benzodiazepines and sedatives; high risk of impulsive lethal overdose and behavioral disinhibition